Cholinesterase inhibitors for alzheimer disease

Do they provide more than symptomatic benefits?

Guk Hee Suh, Seung Ho Ryu, Dong Woo Lee, Changsu Han, Young Su Ju, Baik Seok Kee, Joon Noh Lee, Jae Nam Bae, Jong Hyuk Choi, Dai Jin Kim, Nam Jin Lee, Jun Young Lee, Hyo Jin Go, Jung Seo Yi, Seong Jin Cho, Yang Whan Jeon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: This study aims to examine survival of patients with Alzheimer disease (AD) receiving clinical efficacy of cholinesterase inhibitors (ChEIs) and to compare their survival with those of patients with AD who never received ChEIs and cogni- tively intact old psychiatric outpatients. Design, setting, and Participants: The retrospective cohort study used national mortality data provided by the Korean National Statistics Office and electronic database of 15 general hospitals on older patients who began outpatient treatment with psychiatric medications including ChEIs (N = 3,813). The authors controlled for confounding by using multivariate models and propensity scoring methods. Measurements: Mortality rate of patients with AD receiving ChEIs was compared with those of patients with AD who never received ChEIs and cognitively intact old psychiatric outpatients. Results: Observed additional survival of patients with AD receiving ChEIs (mortality rate: 13.1%), when compared with patients with AD who never received ChEIs (15.4%) was not statistically significant (p = 0.74; hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 0.67-1.59). Patients with AD receiving ChEIs showed higher mortality rate (13.1%) compared with that of cognitively intact old psychiatric outpatients (8.6%) (p <0.001; HR: 1.60, 95% CI: 0.96-2.68). Conclusion: This study does not support that ChEIs increase survival of patients with AD, compared with patients with AD who have never treated with ChEIs. Therefore, all ChEIs should be considered for symptomatic use only and not to be capable of modifying mortality of patients with AD.

Original languageEnglish
Pages (from-to)266-273
Number of pages8
JournalAmerican Journal of Geriatric Psychiatry
Volume19
Issue number3
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Cholinesterase Inhibitors
Alzheimer Disease
Psychiatry
Outpatients
Mortality
Survival
Confidence Intervals
General Hospitals
Cohort Studies
Research Design
Retrospective Studies
Databases

Keywords

  • Alzheimer disease
  • Cholinesterase inhibitors
  • mortality

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Cholinesterase inhibitors for alzheimer disease : Do they provide more than symptomatic benefits? / Suh, Guk Hee; Ryu, Seung Ho; Lee, Dong Woo; Han, Changsu; Ju, Young Su; Kee, Baik Seok; Lee, Joon Noh; Bae, Jae Nam; Choi, Jong Hyuk; Kim, Dai Jin; Lee, Nam Jin; Lee, Jun Young; Go, Hyo Jin; Yi, Jung Seo; Cho, Seong Jin; Jeon, Yang Whan.

In: American Journal of Geriatric Psychiatry, Vol. 19, No. 3, 01.01.2011, p. 266-273.

Research output: Contribution to journalArticle

Suh, GH, Ryu, SH, Lee, DW, Han, C, Ju, YS, Kee, BS, Lee, JN, Bae, JN, Choi, JH, Kim, DJ, Lee, NJ, Lee, JY, Go, HJ, Yi, JS, Cho, SJ & Jeon, YW 2011, 'Cholinesterase inhibitors for alzheimer disease: Do they provide more than symptomatic benefits?', American Journal of Geriatric Psychiatry, vol. 19, no. 3, pp. 266-273. https://doi.org/10.1097/JGP.0b013e3181e56d30
Suh, Guk Hee ; Ryu, Seung Ho ; Lee, Dong Woo ; Han, Changsu ; Ju, Young Su ; Kee, Baik Seok ; Lee, Joon Noh ; Bae, Jae Nam ; Choi, Jong Hyuk ; Kim, Dai Jin ; Lee, Nam Jin ; Lee, Jun Young ; Go, Hyo Jin ; Yi, Jung Seo ; Cho, Seong Jin ; Jeon, Yang Whan. / Cholinesterase inhibitors for alzheimer disease : Do they provide more than symptomatic benefits?. In: American Journal of Geriatric Psychiatry. 2011 ; Vol. 19, No. 3. pp. 266-273.
@article{499fc075413b40ada4ec43e9b0f6d74e,
title = "Cholinesterase inhibitors for alzheimer disease: Do they provide more than symptomatic benefits?",
abstract = "Objective: This study aims to examine survival of patients with Alzheimer disease (AD) receiving clinical efficacy of cholinesterase inhibitors (ChEIs) and to compare their survival with those of patients with AD who never received ChEIs and cogni- tively intact old psychiatric outpatients. Design, setting, and Participants: The retrospective cohort study used national mortality data provided by the Korean National Statistics Office and electronic database of 15 general hospitals on older patients who began outpatient treatment with psychiatric medications including ChEIs (N = 3,813). The authors controlled for confounding by using multivariate models and propensity scoring methods. Measurements: Mortality rate of patients with AD receiving ChEIs was compared with those of patients with AD who never received ChEIs and cognitively intact old psychiatric outpatients. Results: Observed additional survival of patients with AD receiving ChEIs (mortality rate: 13.1{\%}), when compared with patients with AD who never received ChEIs (15.4{\%}) was not statistically significant (p = 0.74; hazard ratio [HR]: 1.03, 95{\%} confidence interval [CI]: 0.67-1.59). Patients with AD receiving ChEIs showed higher mortality rate (13.1{\%}) compared with that of cognitively intact old psychiatric outpatients (8.6{\%}) (p <0.001; HR: 1.60, 95{\%} CI: 0.96-2.68). Conclusion: This study does not support that ChEIs increase survival of patients with AD, compared with patients with AD who have never treated with ChEIs. Therefore, all ChEIs should be considered for symptomatic use only and not to be capable of modifying mortality of patients with AD.",
keywords = "Alzheimer disease, Cholinesterase inhibitors, mortality",
author = "Suh, {Guk Hee} and Ryu, {Seung Ho} and Lee, {Dong Woo} and Changsu Han and Ju, {Young Su} and Kee, {Baik Seok} and Lee, {Joon Noh} and Bae, {Jae Nam} and Choi, {Jong Hyuk} and Kim, {Dai Jin} and Lee, {Nam Jin} and Lee, {Jun Young} and Go, {Hyo Jin} and Yi, {Jung Seo} and Cho, {Seong Jin} and Jeon, {Yang Whan}",
year = "2011",
month = "1",
day = "1",
doi = "10.1097/JGP.0b013e3181e56d30",
language = "English",
volume = "19",
pages = "266--273",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cholinesterase inhibitors for alzheimer disease

T2 - Do they provide more than symptomatic benefits?

AU - Suh, Guk Hee

AU - Ryu, Seung Ho

AU - Lee, Dong Woo

AU - Han, Changsu

AU - Ju, Young Su

AU - Kee, Baik Seok

AU - Lee, Joon Noh

AU - Bae, Jae Nam

AU - Choi, Jong Hyuk

AU - Kim, Dai Jin

AU - Lee, Nam Jin

AU - Lee, Jun Young

AU - Go, Hyo Jin

AU - Yi, Jung Seo

AU - Cho, Seong Jin

AU - Jeon, Yang Whan

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objective: This study aims to examine survival of patients with Alzheimer disease (AD) receiving clinical efficacy of cholinesterase inhibitors (ChEIs) and to compare their survival with those of patients with AD who never received ChEIs and cogni- tively intact old psychiatric outpatients. Design, setting, and Participants: The retrospective cohort study used national mortality data provided by the Korean National Statistics Office and electronic database of 15 general hospitals on older patients who began outpatient treatment with psychiatric medications including ChEIs (N = 3,813). The authors controlled for confounding by using multivariate models and propensity scoring methods. Measurements: Mortality rate of patients with AD receiving ChEIs was compared with those of patients with AD who never received ChEIs and cognitively intact old psychiatric outpatients. Results: Observed additional survival of patients with AD receiving ChEIs (mortality rate: 13.1%), when compared with patients with AD who never received ChEIs (15.4%) was not statistically significant (p = 0.74; hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 0.67-1.59). Patients with AD receiving ChEIs showed higher mortality rate (13.1%) compared with that of cognitively intact old psychiatric outpatients (8.6%) (p <0.001; HR: 1.60, 95% CI: 0.96-2.68). Conclusion: This study does not support that ChEIs increase survival of patients with AD, compared with patients with AD who have never treated with ChEIs. Therefore, all ChEIs should be considered for symptomatic use only and not to be capable of modifying mortality of patients with AD.

AB - Objective: This study aims to examine survival of patients with Alzheimer disease (AD) receiving clinical efficacy of cholinesterase inhibitors (ChEIs) and to compare their survival with those of patients with AD who never received ChEIs and cogni- tively intact old psychiatric outpatients. Design, setting, and Participants: The retrospective cohort study used national mortality data provided by the Korean National Statistics Office and electronic database of 15 general hospitals on older patients who began outpatient treatment with psychiatric medications including ChEIs (N = 3,813). The authors controlled for confounding by using multivariate models and propensity scoring methods. Measurements: Mortality rate of patients with AD receiving ChEIs was compared with those of patients with AD who never received ChEIs and cognitively intact old psychiatric outpatients. Results: Observed additional survival of patients with AD receiving ChEIs (mortality rate: 13.1%), when compared with patients with AD who never received ChEIs (15.4%) was not statistically significant (p = 0.74; hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 0.67-1.59). Patients with AD receiving ChEIs showed higher mortality rate (13.1%) compared with that of cognitively intact old psychiatric outpatients (8.6%) (p <0.001; HR: 1.60, 95% CI: 0.96-2.68). Conclusion: This study does not support that ChEIs increase survival of patients with AD, compared with patients with AD who have never treated with ChEIs. Therefore, all ChEIs should be considered for symptomatic use only and not to be capable of modifying mortality of patients with AD.

KW - Alzheimer disease

KW - Cholinesterase inhibitors

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=79952106122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952106122&partnerID=8YFLogxK

U2 - 10.1097/JGP.0b013e3181e56d30

DO - 10.1097/JGP.0b013e3181e56d30

M3 - Article

VL - 19

SP - 266

EP - 273

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 3

ER -